ClinicalTrials.gov registry snapshot / 2026-07-24

Peptide trials,
without the maze.

Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.

268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program

Study status is not drug rank.

Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.

Official registry finder

Filter the exact records.

Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.

Reset
5matching registry records
Matching recruiting site observations0
Program and recordStatusPhase and enrollmentLocationsPrimary completionRegistry updateSource
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/SRecruitingVerified 2026-07Phase 3460 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Mar 20, 2030estimatedJul 17, 2026ClinicalTrials.govOpen NCT07253285
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 / REIMAGINEYOUNG / Novo Nordisk A/SNot yet recruitingVerified 2026-05Phase 380 estimated0 matching recruitingNo city or postal detail is present for the matching registry rows.Sep 7, 2029estimatedMay 28, 2026ClinicalTrials.govOpen NCT07282613
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/SActive, not recruitingVerified 2026-07Phase 37,101 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Sep 1, 2027estimatedJul 17, 2026ClinicalTrials.govOpen NCT05669755
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/SCompletedVerified 2026-07Phase 32,734 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Nov 19, 2025actualJul 8, 2026ClinicalTrials.govOpen NCT06065540
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/SCompletedVerified 2026-04Phase 31,024 actual0 matching recruitingNo city or postal detail is present for the matching registry rows.Mar 4, 2026actualApr 22, 2026ClinicalTrials.govOpen NCT06221969
Clinical trial finder FAQ

Status, location, and enrollment are different fields.

These answers prevent the most common registry-search errors before a reader follows an official source.

01

Are any Retatrutide clinical trials recruiting?

Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.

02

How do I find a peptide clinical trial near me?

Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.

03

Does Recruiting mean I can join the trial?

No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.

04

Are the drugs in this clinical trial finder FDA approved?

A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.

05

Why do only some registry records show posted results?

11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.

06

How current is the peptide clinical trial data?

The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.

Evidence boundary

A registry finder, not an enrollment service.

A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.

Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.

Read the official API documentation ↗Understand evidence categories →